Quidel Corp Wins FDA Clearance for Solana Molecular Assay
The company has received FDA marketing clearance from the FDA for its Solana C. difficile assay for the direct, qualitative detection of the Clostridium difficile DNA in unformed stool specimens.
CDI symptoms include nausea, fever, watery diarrhea and abdominal pain due to inflammation of the colon.
Solana can process up to 12 different assays or patient samples in each batch run within 35 minutes. — Cynthia Jessup